- Home
- NVNI vs GNTA Comparison
NVNI vs GNTA Comparison
Compare NVNI & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVNI | GNTA |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | Brazil | Italy |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4M | 34.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NVNI | GNTA |
|---|---|---|
| Price | $1.27 | $0.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 93.1K | ★ 124.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.67 | N/A |
| Revenue Next Year | $26.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.71 |
| 52 Week High | $4.94 | $10.00 |
Technical Indicators
Market Signals| Indicator | NVNI | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 32.04 | 44.16 |
| Support Level | $0.30 | $0.71 |
| Resistance Level | $1.64 | $1.70 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 21.33 | 58.33 |
Price Performance
Historical ComparisonAbout NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.